Communiqués Immuneering Corporation

Actions

IMRX

US45254E1073

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
4,070 ^USD	+0,99%		-4,68%	-38,15%

28/09	Immuneering Corporation présente des données lors de la conférence 2026 de l’Association américaine pour la recherche sur le cancer (AACR) consacrée au cancer du pancréas, étayant les mécanismes de l’atebimetinib conçus pour prolonger la survie dans le cancer du pancréas	CI
26/08	Immuneering annonce l'approbation par la FDA d'un nouveau traitement de deuxième ligne pour le cancer du pancréas métastatique et fait le point sur l'essai de phase 3 MAPKeeper 301 de l'atebimetinib	CI

Communiqués

02/10	Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)	GL
28/09	Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer	GL
24/09	Immuneering to Present at the ESMO Congress 2026	GL
10/09	Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival	GL
10/09	Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival	AQ
03/09	Immuneering to Participate in Upcoming Investor Conferences	GL
27/08	Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients	AQ
26/08	Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients	GL
05/08	Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates	GL
21/07	Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition	GL
17/07	Immuneering Corporation Announces Grants of Inducement Awards	GL
15/06	Immuneering Appoints Andrew Gengos as Chief Financial Officer	GL
11/06	Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer	GL
01/06	Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO	GL
21/05	Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy	GL
15/05	Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates	GL
21/04	Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting	GL
20/04	Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond	GL
06/04	Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference	GL
17/03	Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival	GL
06/03	Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates	GL
02/03	Immuneering to Present at the Leerink Global Healthcare Conference	GL
02/03	Immuneering to Present at the Leerink Global Healthcare Conference	AQ
18/02	Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	GL
07/01	Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP	GL